Clinical

Mark A. Socinski, MD, executive director of AdventHealth Cancer Institute, gave insight into treatment resistance and the importance of repeat biomarker testing at the time of disease progression in non–small cell lung cancer (NSCLC).

Iptacopan elicited improved hemoglobin levels measuring at least 2 g/dL higher vs baseline, leading to transfusion independence after 24 weeks in approximately 92.2% of patients with complement inhibitor–naïve paroxysmal nocturnal hemoglobinuria.

Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma are type 2 inflammatory conditions that frequently coexist, the with the latter increasing the symptom burden of the former

A panel of multiple myeloma experts discuss costs associated with relapsed/refractory disease.

Treatment considerations for relapsing multiple myeloma is discussed by key opinion leaders.

The partnership will help develop standards for data transfer to eliminate manual steps used in clinical trials.

A patient’s inability to count while holding their breath can be an indication of respiratory distress in myasthenia gravis.

These factors could provide a scientific basis for consistency evaluations of the quality and efficacy of insulin biosimilars, study authors wrote.

Gene therapies could have a major impact, although the cost and complexities could inhibit their wide rollout, study authors said.

A Danish study of nationwide registries estimated a 39% greater risk of high refractive error among children of mothers with hypertensive disorder of pregnancy (HDP), a complication that affects 5% to 10% of pregnancies.

Patients in this study, who had overall significantly higher scores than controls, fell into 3 categories of psychological risk from temporal lobe epilepsy (TLE) based on analysis with unsupervised machine learning.

Brian Keegan, MD, PhD, and Michael Cameron, MD, FAAD, describe treatment options for patients with atopic dermatitis.

Dr Casey Butrus drives a discussion highlighting typical patient presentations of AD.

The DRCR Retina Network is undertaking research to develop preventive strategies for diabetic eye disease, explained Jennifer K. Sun, MD, MPH, associate professor of ophthalmology and chief of the Center for Clinical Eye Research and Trials, Harvard Medical School; and chair, DRCR Retina Network.

This cross-sectional observational study found several factors associated with whether a patient had sufficient lung cancer risk factor documentation in the electronic health record.

Results from 2 late-stage trials evaluating generalized myasthenia gravis therapies indicated both drugs, rozanolixizumab and zilucoplan, have potential as targeted treatment options.

Mark A. Socinski, MD, executive director of the AdventHealth Cancer Institute, shares his insight on liquid- and tissue-based biopsies and their clinical utility in non–small cell lung cancer (NSCLC).

Investigators wanted to assess endoscopic appearance, wall thickness, histology, and dysphagia score for eosinophilic esophagitis (EoE).

Key opinion leaders discuss clinical and cost considerations for treating patients diagnosed with geographic atrophy.

A medical expert discusses preauthorization requests and requirements for cardiovascular disease treatment, commenting on an abstract presented at the ACC 2023 Annual Scientific Session and Expo and World Congress of Cardiology.

Researchers are beginning work on a double-blind randomized controlled trial to test the results of this preliminary study.

Expert panelists discuss considerations for RRMM treatment strategies.

Jeffrey Matous, MD, leads a panel discussion surrounding the use of bispecifics treatment of relapsed / refractory multiple myeloma.

The American Society for Radiation Oncology (ASTRO) and European Society for Radiotherapy and Oncology (ESTRO) jointly released a clinical guideline on the use of definitive local therapy for the treatment of oligometastatic non–small cell lung cancer (NSCLC).

Investigators found patients with acute coronary syndrome were 3 times more likely to die in the hospital.

The antibody drug conjugate received FDA approval in November 2022.

The data highlight that silent cerebral infarcts represent just a portion of brain injury that occurs in patients with sickle cell disease (SCD), and brain volume can serve as another potential biomarker of brain injury in those with the disease.

In this phase 1 trial, researchers sought to investigate whether ruxolitinib cream is safe and tolerable in children aged 2 to 17 with atopic dermatitis (AD).

People with myasthenia gravis (MG) had a higher risk of hospitalization for COVID-19 compared to the general population and a control group of people with rheumatoid arthritis (RA).

Two-year data on MRI, efficacy, and safety findings from the long-term safety extension study of the investigational Bruton tyrosine kinase (BTK) inhibitor tolebrutinib for relapsing multiple sclerosis were presented in a pair of posters at the American Academy of Neurology 2023 annual meeting.